fda update tirzepatide Says Compounded Must Exit the Market FDA's tirzepatide decision creates uncertainty

Kojima et al., 2020

& Currie, P

2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American college of cardiology/american heart association joint committee on clinical practice guidelines

Phytomedicine 134:155971

Deficits in glutathione have been implicated in aging and a host of diseases including Alzheimer's disease, Parkinson's disease, cardiovascular disease, cancer, Down syndrome and autism

Switching from tirzepatide to retatrutide The safest approach based on current clinical understanding: Stop tirzepatide and allow a washout period of 1-2 weeks (tirzepatide half-life is approximately 5 days) Start retatrutide at 2 mg regardless of your previous tirzepatide dose Titrate up on the standard schedule , every 4 weeks Do not skip steps because you were on high-dose tirzepatide, the glucagon receptor is new territory for your body The rationale is straightforward